Limits...
Large duodenal GIST with massive liver secondaries melting under Imatinib: a case report.

Sankar S, Subramanian M, Arunkumar T, Venu N, Anand K - Cases J (2008)

Bottom Line: Better understanding of the cell of origin and immunohistochmical markers have made this possible.What is interesting in this case is the enormous tumor load at the time of presentation as exemplified by the cross sectional images.This kind of tumor response and patient survival deserves documentation.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Surgical gastroenterology, D-2 Private clinic, Sri Ramachandra Medical College & Research Center, Chennai, 600116, Tamilnadu, India. drsshankar@gmail.com.

ABSTRACT
Gastrointestinal stromal tumors(GIST) have become a well established entity and its taxonomy is no more ambiguous. Better understanding of the cell of origin and immunohistochmical markers have made this possible. Their treatment has been revolutionized with the advent of targeted molecular therapy, namely Imatinib mesylate. Herein we report a rare and interesting case of a thirty year old South Indian Lady with an extremely large Duodenal GIST with massive Liver secondaries. The phenomenon of metastatic GIST responding to Imatinib mesylate is not new. What is interesting in this case is the enormous tumor load at the time of presentation as exemplified by the cross sectional images. This kind of tumor response and patient survival deserves documentation.

No MeSH data available.


Related in: MedlinePlus

Partial response of duodenal tumor.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2570680&req=5

Figure 5: Partial response of duodenal tumor.

Mentions: Anemia was corrected with blood transfusion. Since she had a metastatic GIST, she was started on Imatinib mesylate 400 mg once daily. The follow up CT showed a very dramatic response with almost complete clearance of metastatic deposit in the liver(fig 4). The duodenal tumor regressed in size(Fig 5). Since the Liver metastasis responded dramatically, we offered surgery for the primary duodenal tumor, which patient refused. At the point of writing this article, that is three years and six months after diagnosis, patient is fine and asymptomatic and continues to take Imatinib mesylate.


Large duodenal GIST with massive liver secondaries melting under Imatinib: a case report.

Sankar S, Subramanian M, Arunkumar T, Venu N, Anand K - Cases J (2008)

Partial response of duodenal tumor.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2570680&req=5

Figure 5: Partial response of duodenal tumor.
Mentions: Anemia was corrected with blood transfusion. Since she had a metastatic GIST, she was started on Imatinib mesylate 400 mg once daily. The follow up CT showed a very dramatic response with almost complete clearance of metastatic deposit in the liver(fig 4). The duodenal tumor regressed in size(Fig 5). Since the Liver metastasis responded dramatically, we offered surgery for the primary duodenal tumor, which patient refused. At the point of writing this article, that is three years and six months after diagnosis, patient is fine and asymptomatic and continues to take Imatinib mesylate.

Bottom Line: Better understanding of the cell of origin and immunohistochmical markers have made this possible.What is interesting in this case is the enormous tumor load at the time of presentation as exemplified by the cross sectional images.This kind of tumor response and patient survival deserves documentation.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Surgical gastroenterology, D-2 Private clinic, Sri Ramachandra Medical College & Research Center, Chennai, 600116, Tamilnadu, India. drsshankar@gmail.com.

ABSTRACT
Gastrointestinal stromal tumors(GIST) have become a well established entity and its taxonomy is no more ambiguous. Better understanding of the cell of origin and immunohistochmical markers have made this possible. Their treatment has been revolutionized with the advent of targeted molecular therapy, namely Imatinib mesylate. Herein we report a rare and interesting case of a thirty year old South Indian Lady with an extremely large Duodenal GIST with massive Liver secondaries. The phenomenon of metastatic GIST responding to Imatinib mesylate is not new. What is interesting in this case is the enormous tumor load at the time of presentation as exemplified by the cross sectional images. This kind of tumor response and patient survival deserves documentation.

No MeSH data available.


Related in: MedlinePlus